Miromatrix Medical Inc.
This article was originally published in Start Up
Executive Summary
Regenerative medicine start-up Miromatrix Medical is working to commercialize a technology known as perfusion decellularization. Its proprietary, patent-protected technology involves the decellularization of any vascularized tissue, up to and including whole organs, leaving behind a completely preserved native scaffold (matrix) that retains the original architecture, mechanical properties and vascular network of the tissue or organ. This scaffold can then be repopulated with vascular- and organ-specific regenerative cells and, under controlled conditions in a bioreactor, a biocompatible, functioning organ or tissue is created.